Project M.I.R.A.S
1.1 Short project summary My project involves the conceptualization and development of an innovative approach to modular self-assembling robotic systems. Through its ability to form any complex configuration, the system is highly adaptable to various scenarios and environments. Before delving deeper into the details of my project, I will provide an overview of my background and motivations. 1.2 Background Ever since I first watched the movie "Big Hero 6", I felt amazed by the applications of the so called “microbots”. From that point on, it made me always wonder what would be possible in the real world. When I did the research, I stumbled upon this field of modular robotics. Initially, I was unsure whether to embark on a project focused on electronics and robotics due to my background in programming. On the other side, this year gave me a chance to see the incredible performances of various projects at different science expos. Besides, I took part in the program of CANSAT LU and learned a lot during it, such as microchips, the control of miniature robotics, and the sensors of it. Finally, at school, I took the option Electronics where we dig into similar topics. With this accumulated knowledge and experience I felt confident enough to start this project.
Revolutionizing Metabolic Health: The Therapeutic Potential of Next-Generation Probiotic Akkermansia Strains (Z62, IR119) for Metabolic Syndromes
The human gut microbiome is integral to digestion, overall health, and metabolic disorder imbalances. Recent advancements in fecal microbiota transplantation (FMT) have highlighted the therapeutic promise of restoring healthy gut microbiota in populations with high incidences of diseases. Focusing on fecal DNA samples from healthy Asian individuals, this study examines the potential of novel Akkermansia strains, specifically Akkermansia muciniphila (Z62) and Akkermansia massiliensis (IR119), as next-generation probiotics for mitigating metabolic syndrome. A key aspect of the study is the investigation of short-chain fatty acids (SCFAs), which are produced and play a crucial role in regulating metabolic processes. SCFAs such as butyrate, acetate, and propionate are essential for energy provision to colon cells and exerting anti-inflammatory effects. The methodology involves selecting two Akkermansia strains, analyzing them through 16S rRNA and WGS, evaluating their growth and survival rates under acidic and bile-salt conditions, alongside their cell adhesion capabilities. The study focuses on the production of key short-chain fatty acids (SCFAs) and tryptophan derivatives by bacteria in regulating metabolic processes, as well as their anti-inflammatory effects on colon cells. Through in vitro assays, both strains exhibited survival in acidic/bile-rich conditions, though Z62 demonstrated superior adhesion to Caco-2 cells, suggesting a higher colonization potential. Metabolomic analysis revealed both strains produce SCFAs, including propionic and acetic acids, and indole metabolites, such as indole-3-propionic acid and indole-3-acetic acid, which are known to influence lipid metabolism and insulin sensitivity. In adipocyte cell models, IR119 significantly reduced lipid accumulation, while Z62 increased lipid presence. Furthermore, IR119 reduced pro-inflammatory cytokine levels, including IL-6 and TNF-α, suggesting potential for inflammation mitigation. The future potential of IR119 as a therapeutic probiotic is extraordinary in addressing complex metabolic and inflammatory diseases, which open new avenues for managing chronic inflammatory conditions like type 2 diabetes and cardiovascular disease. Future clinical trials could refine IR119’s efficacy, positioning it as a leading probiotic in preventive and therapeutic contexts.